author-photo

L Kappos

University of Düsseldorf

151

Papers

1493

Citations

Citation Trend

Filter By

Papers (110) Sort By

Journal Conference Others

067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials

2021
Show All
- Source
- Cite
- Save
Citations (0)
Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis

2021 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (3)
Rethinking MS in Europe Prioritising Timely Integrated Services for People with Multiple Sclerosis

2020
Show All
- Source
- Cite
- Save
Citations (0)
Creating accurate reference segmentations of deep GM structures in MS patients by fast semi-automated outlining

2018 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (0)
Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis

2018 Multiple sclerosis and related disorders
Show All
- Source
- Cite
- Save
Citations (3)
Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions

2018 Multiple sclerosis and related disorders
Show All
- Source
- Cite
- Save
Citations (1)
Quantification of spinal cord atrophy in MS: which software, which vertebral level, spinal cord or brain MRI? A multi-centric, longitudinal comparison of three different volumetric approaches.

2018 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (7)
Long-term Disease Control with Fingolimod in RRMS Patients with Active Disease

2018 Multiple sclerosis and related disorders
Show All
- Source
- Cite
- Save
Citations (0)
Impact of Gadolinium-enhancing (GD+) Lesions on No Evidence of Disease Activity (NEDA) Status in Subcutaneous Interferon Beta-1a (SC IFNβ-1a)-treated Patients

2018 Multiple sclerosis and related disorders
Show All
- Source
- Cite
- Save
Citations (0)
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial

2018 Multiple sclerosis and related disorders
Show All
- Source
- Cite
- Save
Citations (2)